财经快讯|复星医药:复星凯特奕凯达二线适应症预计今年获批
复星医药近日接受机构调研时表示,复星凯特奕凯达的二线适应症预计今年获批,适应人群拓展将进一步建立产品的领导地位。其他新产品/适应症也在顺利推进临床,如惰性淋巴瘤、套细胞淋巴瘤、急性淋巴性白血病等。未来随着患者数增加,产品成本端也有望进一步下降。
Statement:
The content of this article does not represent the views of fxgecko website. The content is for reference only and does not constitute investment suggestions. Investment is risky, so you should be careful in your choice! If it involves content, copyright and other issues, please contact us and we will make adjustments at the first time!